Rivaroxaban vs. Warfarin in Japanese Patients With Non-Valvular Atrial Fibrillation in Relation to Age : Insight From J-ROCKET AF

• Hori Masatsugu

  Osaka Medical Center for Cancer and Cardiovascular Diseases

• Matsumoto Masayasu

  Department of Clinical Neuroscience and Therapeutics, Hiroshima University

• Tanahashi Norio

  Department of Neurology, Saitama Medical University International Medical Center

• Momomura Shin-ichi

  Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University

• Uchiyama Shinichiro

  Department of Neurology, Tokyo Women’s Medical University

• Goto Shinya

  Department of Medicine (Cardiology), Tokai University School of Medicine

• Izumi Tohru

  Department of Cardio-angiology, Kitasato University School of Medicine

• Koretsune Yukihiro

  Institute for Clinical Research, Osaka National Hospital

• Kajikawa Mariko

  Bayer Yakuhin

• Kato Masaharu

  Bayer Yakuhin

• Ueda Hitoshi

  Bayer Yakuhin

• Iekushi Kazuma

  Bayer Yakuhin

• Yamanaka Satoshi

  Bayer Yakuhin

• Tajiri Masahiro

  Bayer Yakuhin

• on behalf of the J-ROCKET AF Study Investigators

書誌事項

タイトル別名

• Rivaroxaban vs. Warfarin in Japanese Patients With Non-Valvular Atrial Fibrillation in Relation to Age
• – Insight From J-ROCKET AF –

抄録

Background: The J-ROCKET AF study found that rivaroxaban was non-inferior to warfarin with respect to the principal safety outcome in patients with atrial fibrillation (AF). The aim of this subgroup analysis was to assess the safety and efficacy of rivaroxaban and warfarin in relation to patient age. Methods and Results: A total of 39.0% were elderly (aged ≥75 years). In elderly patients, the principal safety outcome occurred at 25.05%/year with rivaroxaban vs. 16.95%/year on warfarin (hazard ratio [HR], 1.49; 95% confidence interval [CI]: 1.02–2.16), whereas the primary efficacy endpoint occurred at 2.18%/year vs. 4.25%/year (HR, 0.51; 95% CI: 0.20–1.27), respectively. There were significant interactions in the principal safety outcomes of rivaroxaban compared with warfarin between the elderly and non-elderly groups, but not in the primary efficacy endpoints (P=0.04 and 0.82 for both interactions, respectively). Furthermore, in elderly patients, in the rivaroxaban group there was a trend to increase the principal safety outcome regardless of renal function. In elderly patients with preserved renal function, however, patients on rivaroxaban had a marginally favorable trend in the primary efficacy endpoint incidence rate compared with patients on warfarin. Conclusions: There is a need to carefully consider the risks and benefits of therapy with rivaroxaban in elderly patients with non-valvular AF.  (Circ J 2014; 78: 1349–1356)<br>

収録刊行物

• Circulation Journal

  Circulation Journal 78 (6), 1349-1356, 2014

  一般社団法人 日本循環器学会

キーワード

• Atrial fibrillation
• Elderly
• Oral anticoagulation
• Stroke prevention

詳細情報

• CRID: 1390001205107693312
• NII論文ID: 130003391124
• NII書誌ID: AA11591968
• DOI: 10.1253/circj.cj-13-1324
• COI: 1:STN:280:DC%2BC2cngvFWltQ%3D%3D
• ISSN: 13474820
• ISSN: 13469843
• NDL書誌ID: 025461897
• PubMed: 24705469
• Web Site: http://id.ndl.go.jp/bib/025461897
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I025461897
• Web Site: https://www.jstage.jst.go.jp/article/circj/78/6/78_CJ-13-1324/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2015132741
• 本文言語コード: en
• データソース種別:
  • JaLC
  • NDL
  • Crossref
  • PubMed
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可